<listing id="lvl5n"><big id="lvl5n"><progress id="lvl5n"></progress></big></listing>

<pre id="lvl5n"><span id="lvl5n"><th id="lvl5n"></th></span></pre>

<big id="lvl5n"></big>

<listing id="lvl5n"></listing>

<big id="lvl5n"><video id="lvl5n"><progress id="lvl5n"></progress></video></big>

      <menuitem id="lvl5n"><dfn id="lvl5n"></dfn></menuitem>

        <del id="lvl5n"></del><listing id="lvl5n"></listing>
        <sub id="lvl5n"></sub>

              <video id="lvl5n"></video><dfn id="lvl5n"></dfn>

              網站檢索

              藥明生物子公司藥明海德與全球疫苗巨頭成功簽訂疫苗長期生產供應合同

              時間:2020-02-25 10:32來源:藥明生物 點擊:0
              藥明生物子公司藥明海德與全球疫苗
              巨頭成功簽訂疫苗長期生產供應合同
              WuXi Biologics' Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader
              (*Please scroll down for English news.)
              中國,上海
              2020年2月18日
               
              全球領先的開放式生物制藥技術平臺公司藥明生物(WuXi Biologics, 2269.HK)今日宣布,其從事疫苗合同定制研發生產(CDMO)服務的子公司藥明海德已經與一家全球疫苗巨頭達成戰略合作伙伴關系,簽署了長達二十年的疫苗生產供應合同,將在愛爾蘭新建一座疫苗專用生產基地服務全球市場,該合同總金額約30億美元。
              根據該合同,藥明海德已經著手在愛爾蘭新建一座集疫苗原液、制劑、工藝放大、質量控制(QC)實驗室于一體的工業化生產及供應基地,專門生產該客戶的創新性疫苗以供應全球市場。該生產基地預計2022年投入運行。
               
              2019年11月,藥明海德宣布投資2.4億美元建設疫苗原液及制劑廠等生產基地。該基地將位于藥明生物愛爾蘭園區內,毗鄰藥明生物正在建設的全球領先生物制藥“未來工廠”生產基地,后者預計將于2021年投入商業化生產。
               
              藥明海德是藥明生物與位于上海的海利生物(股票代碼:603718.SH)共同成立的合資企業,致力于打造全球疫苗行業領先的一體化能力和技術平臺,提供疫苗合同定制研發生產(CDMO)服務,賦能全球疫苗行業研發和生產。
              藥明生物子公司藥明海德與全球疫苗巨頭成功簽訂疫苗長期生產供應合同
               
              “此項戰略合作開創了疫苗行業全新合作模式,對藥明生物、藥明海德乃至全球疫苗產業而言都具有歷史性意義。由于生產工藝高度復雜、分析檢測方法繁多以及法規標準嚴格,疫苗生產難度頗高,生產過程中的工藝質量控制對確保產品質量也至關重要。此次與全球疫苗巨頭達成戰略合作伙伴關系,獨家生產一款創新性疫苗并供應全球市場,進一步彰顯了藥明生物、藥明海德領先的技術優勢和全球高標準質量體系。”藥明生物首席執行官兼藥明海德董事長陳智勝博士表示,“疫苗CDMO業務是藥明生物發展的新增長點之一,該項目的啟動將推動疫苗業務進一步助力公司持續高速增長。藥明生物將攜手藥明海德繼續通過健全強大的全球供應鏈網絡,賦能合作伙伴生產高質量治療性蛋白藥物及疫苗產品,造福全球病患,保護人類健康。”
               
              關于藥明生物
               
               
              藥明生物(股票代碼:2269.HK)作為一家香港上市公司,是全球領先的開放式、一體化生物制藥能力和技術賦能平臺。公司為全球生物制藥公司和生物技術公司提供全方位的端到端研發服務,幫助任何人、任何公司發現、開發及生產生物藥,實現從概念到商業化生產的全過程,加速全球生物藥研發進程,降低研發成本,造福病患。截至2019年6月30日,在藥明生物平臺上研發的綜合項目達224個,包括106個處于臨床前研究階段,102個在臨床早期(I期,II期)階段,15個在后期臨床(III期)以及1個在商業化生產階段。預計到2022年,公司在中國、愛爾蘭、新加坡、美國規劃的生物制藥生產基地合計產能將超過28萬升,這將有力確保公司通過健全強大的全球供應鏈網絡為客戶提供符合全球質量標準的生物藥。
              如需更多信息,請訪問:www.wuxibiologics.com.cn。
               
               
              WuXi Biologics’ Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader
               
              SHANGHAI, China, 
              Feb 18, 2020
               
               
              WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing,announced that WuXi Vaccines, its joint venture with Shanghai Hile Bio-technology(603718.SH), has entered into a strategic partnership with a global vaccine leader and signed a 20-year vaccine manufacturing contract valued approximately $3 billion USD, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial vaccine products for the global market.
               
               
              Per the contract signed, WuXi Vaccines will build an integrated vaccine manufacturing facility including drug substance manufacturing (DS), drug product manufacturing (DP), Manufacture Science and Technology Labs (MS&T) as well as Quality Control labs (QC). The facility will be dedicated to manufacture one of its partner’s vaccine products for the global market. The new facility is expected to be operational in 2022.
               
               
              In Nov 2019, WuXi Vaccines announced 240 million USD investment to build the new vaccine manufacturing facility in Ireland. The facility is located within the WuXi Biologics Campus adjacent to the “Factory of the Future” biologics drug substance manufacturing facility which is scheduled for commercial manufacturing in 2021.
               
               
              WuXi Vaccines is a joint venture company established between WuXi Biologics and Shanghai Hile Bio-technology (stock code: 603718.SH). The business model of WuXi Vaccines is to build world-class integrated platforms and CDMO model to enable global companies to develop and manufacture vaccines.
               
               
              “This is a historic moment for WuXi Biologics and WuXi Vaccines as well as for the global vaccine industry. Due to process complexity, extensive analytic testing and rigorous regulatory standards, vaccines are difficult to manufacture and process and quality control are extremely critical for the quality of the product. This partnership with a global vaccine leader to exclusively manufacture a vaccine for the global market, first of its kind in the industry, is a further testimony to the technical strengths and premier quality demonstrated by WuXi Vaccines,” commented Dr. Chris Chen, CEO of WuXi Biologics and Chairman of WuXi Vaccines,“Vaccine CDMO is one of the next growth areas for WuXi Biologics. Once this project is initiated, our vaccine business will contribute substantially to the growth of WuXi Biologics. WuXi Biologics together with WuXi Vaccines will continue to provide our global partners with a robust and premier-quality supply chain network to produce high quality biologic and vaccine products to benefit patients worldwide and to protect human being globally, initially with therapeutic proteins and now with vaccines.”
               
              About WuXi Biologics
               
               
               
              WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of June 30, 2019, there were a total of 224 integrated projects, including 106 projects in pre-clinical development stage, 102 projects in early-phase (phase I and II) clinical development, 15 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, Singapore, and the U.S. exceeding 280,000 liters by 2022, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
              來源:藥明生物
               

              (責任編輯:薛海湘)
              關于我們 | 聯系我們 | 版權聲明 | 隱私保護 | 法律責任
            1. 版權所有:江蘇省外商投資企業協會 Copyright ?2019 jswqxh.org.cn All Rights Reserved
            2. 協會地址:南京市中華路50號國貿大廈29樓 郵編:210001 傳真:025-52323761 郵箱:js_wzxh@163.com
            3. 網站備案/許可證號: 蘇ICP備14010449號-1 蘇公網安備:32010402000614號

            4. 掃一掃關注我
              日本一级黄色片在线40分_亚洲男人在线天堂2019_日本一区二区三区不卡视频_国内精品视频在线观看九九
              <listing id="lvl5n"><big id="lvl5n"><progress id="lvl5n"></progress></big></listing>

              <pre id="lvl5n"><span id="lvl5n"><th id="lvl5n"></th></span></pre>

              <big id="lvl5n"></big>

              <listing id="lvl5n"></listing>

              <big id="lvl5n"><video id="lvl5n"><progress id="lvl5n"></progress></video></big>

                  <menuitem id="lvl5n"><dfn id="lvl5n"></dfn></menuitem>

                    <del id="lvl5n"></del><listing id="lvl5n"></listing>
                    <sub id="lvl5n"></sub>

                          <video id="lvl5n"></video><dfn id="lvl5n"></dfn>